Neuromodulation Market (By Application, Technology, Region and Company) and Forecast to 2021 – Global Analysis
Date: Apr-2016 | Id: MACRC-0034 | Geographical Scope: Global | Publisher: DPI Research
The Global market for Neuromodulation is projected to reach more than US$5 Billion by the end of 2021 growing at a CAGR of around XX% from 2016 to 2021. Market growth can be attributed to factors such as rising geriatric population, increasing prevalence of neurological diseases, strong product pipeline offered by the players. In addition, rapid advances in the field of neuromodulation and development of minimally invasive techniques have greatly expanded the market. High cost of treatment and negative social perception is restraining the growth of neuromodulation market. North America is seen as the dominant player in the neuromodulation market followed by Europe, Asia–Pacific, and rest of the world (RoW) in 2015. In the coming years, the neuromodulation market is expected to witness the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to increase revenues for the manufacturers of devices involved in neuromodulation. Spinal cord stimulation segment dominated the neuromodulation market with more than XX% share in 2015. But its market share will dwindle in the forecasting period due to the highest growth rate of deep brain stimulation. It is expected that deep brain stimulation will grasp nearly 20% market share by the year end of 2021. Chronic Pain is identified as the largest application segment of the neuromodulation market. Urinary and Fecal Incontinence(UFI) is the second leading segment for neuromodulation market. Refractory epilepsy stands at the third spot with more than XX% share in 2015. Parkinson’s disease holds the fourth highest share being followed by Gastroparesis. Essential Tremor and Dystonia are the other leading application segment for neuromodulation market. Further, prudent analysis has been done on the competitor’s part, where three major players grab XX% of the global market by revenue. Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro are the key influencers with their products in the Neuromodulation market. Merger & acquisitions, partnerships, collaborations and extending distribution networks are few important factors for their dominance. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report concludes with the profiles of major players in the global neuromodulation such as Medtronic, Boston Scientific, St Jude Medical, Liva Nova and Nevro. The major market players are evaluated on various parameters such as company overview, product portfolio, and sales analysis of neuromodulation segment from 2010 to 2021. The report also entails major drivers and challenges of neuromodulation market. Neuromodulation Market: Segmentation Neuromodulation market is classified on the basis of technology, application, company and geography. Based on Technology, Neuromodulation market can be segmented as follows: • Spinal Cord Stimulation • Deep Brain Stimulation • Sacral Nerve Stimulation • Vagus Nerve Stimulation • Other Technologies Based on Application, Neuromodulation market can be segmented as follows: • Chronic Pain • Parkinson’s Disease • Urinary Fecal Incontinence • Refractory Epilepsy • Essential Tremor • Dystonia • Gastroparesis • Treatment Resistant Depression(TRD) • Obsessive Compulsive Disorder(OCD) • Other Applications Based on Geography, Neuromodulation market can be segmented as follows: • North America • Europe • Asia Pacific • Latin America • Rest of the World (ROW) Based on Company, Neuromodulation market can be segmented as follows: • Medtronic • Boston Scientific • St Jude Medical • Liva Nova(Cyberonics) • Nevro
Table of Contents 1. Executive Summary 2. Global – Neuromodulation Market & Forecast (2010 – 2021) 3. Global – Neuromodulation Market Share Outlook 3.1 By Technology – Neuromodulation Market Share Outlook 3.2 By Region – Neuromodulation Market Share Outlook 3.3 By Application – Neuromodulation Market Share Outlook 3.4 By Company – Neuromodulation Market Share Outlook 4. Global Neuromodulation Market – By Technology (2010 – 2021) 4.1 Overall Neuromodulation Market & Forecast – By Technology 4.2 Spinal Cord Stimulation Market Revenue & Forecast 4.3 Deep Brain Stimulation Market Revenue & Forecast 4.4 Sacral Nerve Stimulation Market Revenue & Forecast 4.5 Vagus Nerve Stimulation Market Revenue & Forecast 4.6 Other Technologies Market Revenue & Forecast 5. Global Neuromodulation Market – By Regional Outlook (2010 – 2021) 5.1 Region wise – Overall Neuromodulation Market Revenue & Forecast 5.2 North America – Neuromodulation Market Revenue & Forecast 5.3 Europe – Neuromodulation Market Revenue & Forecast 5.4 Asia Pacific – Neuromodulation Market Revenue & Forecast 5.5 Latin America – Neuromodulation Market Revenue & Forecast 5.6 Rest of the World (ROW) – Neuromodulation Market Revenue & Forecast 6. Global Neuromodulation Market – By Application (2010 – 2021) 6.1 By Application – Overall Neuromodulation Market Revenue & Forecast 6.2 Chronic Pain – Neuromodulation Market & Forecast 6.3 Parkinson’s Disease – Neuromodulation Market & Forecast 6.4 Urinary Fecal Incontinence – Neuromodulation Market & Forecast 6.5 Refractory Epilepsy – Neuromodulation Market & Forecast 6.6 Essential Tremor – Neuromodulation Market & Forecast 6.7 Dystonia – Neuromodulation Market & Forecast 6.8 Gastroparesis – Neuromodulation Market & Forecast 6.9 Treatment Resistant Depression(TRD) – Neuromodulation Market & Forecast 6.10 Obsessive Compulsive Disorder(OCD) – Neuromodulation Market & Forecast 6.11 Other Application – Neuromodulation Market & Forecast 7. Competitive Landscape 7.1 Mergers & Acquisitions 7.2 Agreements, Collaborations & Partnerships 8. Key Companies Analysis 8.1 Medtronic 8.1.1 Business Overview 8.1.2 Neuromodulation Products Portfolio 8.1.2.1 Deep Brain Stimulation for Movement Disorders 8.1.2.2 Deep Brain Stimulation for Psychiatric Disorders 8.1.2.3 Gastric Electrical Stimulation 8.1.2.4 Percutaneous Tibial Neuromodulation 8.1.2.5 Sacral Neuromodulation 8.1.2.6 Spinal Cord Stimulation 8.1.3 Neuromodulation Sales Analysis & Forecast 8.2 Boston Scientific 8.2.1 Business Overview 8.2.2 Neuromodulation Products Portfolio 8.2.2.1 Spinal Cord Stimulator Systems 8.2.2.2 Deep Brain Stimulation (DBS) System 8.2.3 Neuromodulation Sales Analysis & Forecast 8.3 St Jude Medical 8.3.1 Business Overview 8.3.2 Neuromodulation Products Portfolio 8.3.2.1 Spinal Cord Stimulation 8.3.2.2 Dorsal Root Ganglion (DRG) Stimulation 8.3.2.3 Radiofrequency Therapy 8.3.3 Neuromodulation Sales Analysis & Forecast 8.4 Liva Nova(Cyberonics) 8.4.1 Business Overview 8.4.2 Neuromodulation Products Portfolio 8.4.2.1 VNS Therapy System 8.4.2.2 VNS for the Treatment of Epilepsy 8.4.2.3 VNS for the Treatment of TRD 8.4.2.4 Liva Nova Neuromodulation Recent Developments 8.4.3 Neuromodulation Sales Analysis & Forecast 8.5 Nevro 8.5.1 Business Overview 8.5.2 Neuromodulation Products Portfolio 8.5.2.1 HF10 Therapy 8.5.2.2 Senza System 8.5.3 Neuromodulation Sales Analysis & Forecast 9. Neuromodulation Market – Growth Drivers 9.1 Rapid Advancement in the Field of Neuromodulation Market 9.2 Expansion of Indications Fuel the Growth of Neuromodulation Market 9.3 Developing Markets Boon for the Manufacturers to Upsurge the Growth 9.4 Ageing Population & Life Expectancy Boost Growth for the Neurovascular Intervention Market 10. Neuromodulation Market – Challenges 10.1 Unwillingness to Invasive Procedures of Deep Brain Stimulation 10.2 Regulatory Standards and Compliance Impede the Neuromodulation Market 10.3 Negative Social Perception 10.4 Political Uncertainties 10.5 Healthcare Legislative Reform Measures Have Adversely Effected to the Manufacturers
Related reports
Early Cardiogenic Shock Devices
$4500-$6600